TY  - GEN
AU  - Zeidner,Joshua F
AU  - Foster,Matthew C
AU  - Blackford,Amanda L
AU  - Litzow,Mark R
AU  - Morris,Lawrence E
AU  - Strickland,Stephen A
AU  - Lancet,Jeffrey E
AU  - Bose,Prithviraj
AU  - Levy,M Yair
AU  - Tibes,Raoul
AU  - Gojo,Ivana
AU  - Gocke,Christopher D
AU  - Rosner,Gary L
AU  - Little,Richard F
AU  - Wright,John J
AU  - Doyle,L Austin
AU  - Smith,B Douglas
AU  - Karp,Judith E
TI  - Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)
SN  - 1873-5835
PY  - 2019///0403
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Cytarabine
KW  - Daunorubicin
KW  - Female
KW  - Flavonoids
KW  - Humans
KW  - Leukemia, Myeloid, Acute
KW  - diagnosis
KW  - Male
KW  - Middle Aged
KW  - Mitoxantrone
KW  - Piperidines
KW  - Risk Factors
N1  - Publication Type: Clinical Trial, Phase II; Comparative Study; Letter; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1016/j.leukres.2018.08.005
ER  -